


**SUPPLEMENTARY EUROPEAN SEARCH  
REPORT**

 Application number:  
EP 19 87 62 03

**Classification of the application (IPC):**  
 A61K 39/395, A61P 35/00, C07K 14/47, C07K 16/18, G01N 33/53

**Technical fields searched (IPC):**  
 C07K, A61K, A61P

**DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
X	<b>HALE D.F. ET AL:</b> "Pre-specified interim analysis of a randomized phase IIb trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients" <i>ANNALS OF ONCOLOGY</i> NL 01 October 2018 (2018-10-01), vol. 29, no. S8, DOI: 10.1093/annonc/mdy288.001, ISSN: 0923-7534, page viii400, XP055934181 * the whole document *	1-15
T	<b>&amp; ESMO:</b> "ESMO 2018: Publication schedule for accepted abstracts", European Society for Medical Oncology, October 2018 (2018-10) URL: <a href="https://www.esmo.org/meetings/past-meetings/esmo-2018-congress/Press-Media">https://www.esmo.org/meetings/past-meetings/esmo-2018-congress/Press-Media</a> [retrieved on 22 June 2022 (2022-06-22)] XP002806893	
A	<b>COSTA RICARDO ET AL:</b> "Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development" <i>CANCER TREATMENT REVIEWS, ELSEVIER, AMSTERDAM, NL</i> , 05 January 2017 (2017-01-05), vol. 53, DOI: 10.1016/J.CTRV.2016.12.010, ISSN: 0305-7372, pages 111-119, XP029903749	1-15
A	<b>DE LA CRUZ LUCY M ET AL:</b> "Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer" <i>ANNALS OF SURGICAL ONCOLOGY, SPRINGER INTERNATIONAL PUBLISHING, CHAM</i> , 16 July 2018 (2018-07-16), vol. 25, no. 10, DOI: 10.1245/S10434-018-6620-5, ISSN: 1068-9265, pages 2852-2857, XP036617102	1-15
A	<b>JACKSON D.O. ET AL:</b> "Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression" <i>ANNALS OF ONCOLOGY</i> NL 01 October 2016 (2016-10-01), vol. 27, no. S6, DOI: 10.1093/annonc/mdw378.23, ISSN: 0923-7534, page vi366, XP055934280	1-15

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search The Hague	Date of completion of the search 22 June 2022	Examiner Galli, Ivo
------------------------------	--	------------------------

**CATEGORY OF CITED DOCUMENTS**

X: particularly relevant if taken alone	P: intermediate document
Y: particularly relevant if combined with another document of the same category	T: theory or principle underlying the invention
A: technological background	E: earlier patent document, but published on, or after the filing date
O: non-written disclosure	D: document cited in the application
& : member of the same patent family, corresponding document	L: document cited for other reasons

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.



## SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:  
EP 19 87 62 03

### DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
A	<p><b>MITTENDORF E.A. ET AL:</b> "Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients" <i>ANNALS OF ONCOLOGY</i> NL 01 September 2014 (2014-09-01), vol. 25, no. 9, DOI: 10.1093/annonc/mdu211, ISSN: 0923-7534, pages 1735-1742, XP055933939 * the whole document *</p>	1-15
A	<p><b>GALL VICTOR A. ET AL:</b> "Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells" <i>CANCER RESEARCH</i> US 01 October 2017 (2017-10-01), vol. 77, no. 19, pages 5374-5383 URL: <a href="https://aacrjournals.org/cancerres/article-pdf/77/19/5374/2756102/5374.pdf">https://aacrjournals.org/cancerres/article-pdf/77/19/5374/2756102/5374.pdf</a> , ISSN: 0008-5472, XP055934226</p>	1-15
A	<p><b>SCHNEBLE ERIKA J. ET AL:</b> "Abstract 2558: HLA-A2 and HER2 expression levels as clinical prognostic factors in breast cancer patients: implications for peptide cancer vaccine trials" <i>CLINICAL RESEARCH</i>, 30 September 2014 (2014-09-30), vol. 74, no. 19S URL: <a href="http://dx.doi.org/10.1158/1538-7445.AM2014-2558">http://dx.doi.org/10.1158/1538-7445.AM2014-2558</a> , XP055934407</p>	1-15
X,P	<p><b>CLIFTON G. TRAVIS ET AL:</b> "Initial safety analysis of a randomized phase II trial of nelipepimut-S+?GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors" <i>CLINICAL IMMUNOLOGY</i> AMSTERDAM, NL 01 April 2019 (2019-04-01), vol. 201, DOI: 10.1016/j.clim.2019.02.011, ISSN: 1521-6616, pages 48-54, XP055934402 * the whole document *</p>	1-15

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search The Hague	Date of completion of the search 22 June 2022	Examiner Galli, Ivo
------------------------------	--	------------------------

### CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone	P: intermediate document
Y: particularly relevant if combined with another document of the same category	T: theory or principle underlying the invention
A: technological background	E: earlier patent document, but published on, or after the filing date
O: non-written disclosure	D: document cited in the application
& : member of the same patent family, corresponding document	L: document cited for other reasons

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.